HANOVER, MD, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next ...
MIAMI--(BUSINESS WIRE)--New Generation Computing, Inc. (NGC), a leading provider of digital supply chain solutions, today announced that Weissman, a premier designer of dancewear and costumes, is ...
Processa Pharmaceuticals has dosed the first subject in its Phase II clinical trial of Next Generation Capecitabine (NGC-Cap) to treat patients with advanced or metastatic breast cancer. This global, ...
(RTTNews) - Processa Pharmaceuticals, Inc. (PCSA) reported preliminary Phase 2 data showing that its lead oncology candidate, NGC-Cap, a combination of PCS6422 and capecitabine, significantly ...
Processa Pharmaceuticals (NASDAQ:PCSA) stock rallied 25% in morning trading Friday after the company said it plans to expand development of NGC-Cap into breast cancer to provide a “more efficient” ...
HANOVER, MD, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback